ReviewJournal of translational medicine2026
CSDE1 in tumour immunology: spatiotemporal translational reprogramming and immune microenvironment remodeling.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tumour immune microenvironment (TIME) can be considered a dynamic ecosystem, which requires rapid proteomic adaptation for immune evasion. While transcriptional control is undoubtedly significant, post-transcriptional mechanisms, most notably translational regulation, facilitate immediate proteome rewiring. Cold Shock Domain Containing E1 (CSDE1), an RNA-binding protein, has emerged as a pivotal upstream regulator of translational control, orchestrating multiple facets of mRNA metabolism, including translation initiation, elongation, and stability. While its context-dependent roles in tumourigenesis are recognised, the function of CSDE1 in immune regulation remains incompletely understood. MAIN BODY: This review synthesises emerging evidence to position CSDE1 as a central architect of immunosuppression through spatiotemporal translational reprogramming. The present study delineates the manner in which CSDE1 facilitates tumour-intrinsic immune evasion by suppressing antigen presentation and neutralising immunogenic signalling (e.g. cGAS-STING), while concurrently dictating the fates of immune cells - ranging from the development of haematopoietic stem cells to the differentiation of T and B cells. These findings are integrated to propose a novel conceptual framework of spatiotemporal translational reprogramming. This framework posits that CSDE1 decodes the cellular context to dynamically configure translational output across temporal (tumour initiation, progression, therapy resistance) and spatial (cytoplasm, nucleoplasmic reticulum, stress granules, immunological synapse) dimensions. Finally, we explore the therapeutic targeting of CSDE1 through combinatory genotoxic therapy, neoantigen vaccines, immunotherapy sensitisation, and physical stimulation, proposing CSDE1 as a novel therapeutic nexus to overcome resistance in tumour immunotherapy. CONLUSIONS: CSDE1 has been identified as a central context-decoder and a promising therapeutic nexus in the TIME. However, its duality and essential physiological roles pose significant translational challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.